Cyclooxygenase-2 in hepatocellular carcinoma

Cancer Treatment Reviews

Volumn 32, Issue 1, 2006, Pages 28-44

  Wu, Tong ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cyclooxygenase 2; Hepatocellular carcinoma; Prostaglandin E2

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA INTERFERON; CELECOXIB; CORIOLIC ACID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DIMORPHECOLIC ACID; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; FLUOROURACIL; GLITAZONE DERIVATIVE; IBUPROFEN; INDOMETACIN; INDUCIBLE NITRIC OXIDE SYNTHASE; IRINOTECAN; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PIRINIXIC ACID; PROSTAGLANDIN; RIBAVIRIN; SCATTER FACTOR RECEPTOR; TROGLITAZONE; UNINDEXED DRUG; VASCULOTROPIN; YTTRIUM 90;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOPROPHYLAXIS; ENZYME MECHANISM; GROWTH REGULATION; HEPATITIS C; HUMAN; IN VITRO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOLECULAR INTERACTION; NONHUMAN; PROTEIN TARGETING; REVIEW; SECONDARY PREVENTION; SIDE EFFECT; SIGNAL TRANSDUCTION; SYSTEMIC THERAPY; UNITED STATES;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CYCLOOXYGENASE 2; DINOPROSTONE; ENZYME INHIBITORS; FATTY ACIDS, OMEGA-3; HUMANS; LIVER; LIVER NEOPLASMS; NITRIC OXIDE SYNTHASE TYPE II; PPAR ALPHA; PPAR GAMMA; PROSTAGLANDINS E; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 31544468915     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2005.10.004     Document Type: Review

References (217)

1. D.M. Parkin F. Bray J. Ferlay et al. Estimating the world cancer burden: Globocan 2000 Int J Cancer 94 2001 153-156
2. A.M. Di Bisceglie Epidemiology and clinical presentation of hepatocellular carcinoma J Vasc Interv Radiol 13 2002 S169-S171
3. J. Bruix J.M. Llovet Prognostic prediction and treatment strategy in hepatocellular carcinoma Hepatology 35 2002 519-524
4. H.B. El-Serag Hepatocellular carcinoma: Recent trends in the United States Gastroenterology 127 2004 S27-S34
5. H.B. El-Serag A.C. Mason Rising incidence of hepatocellular carcinoma in the United States N Engl J Med 340 1999 745-750
6. W.B. Coleman Mechanisms of human hepatocarcinogenesis Curr Mol Med 3 2003 573-588
7. M. Kondo H. Yamamoto H. Nagano et al. Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma Clin Cancer Res 5 1999 4005-4012
8. H. Koga S. Sakisaka M. Ohishi et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: Relevance to tumor dedifferentiation Hepatology 29 1999 688-696
9. G. Shiota M. Okubo T. Noumi et al. Cyclooxygenase-2 expression in hepatocellular carcinoma Hepatogastroenterology 46 1999 407-412
10. S.H. Bae E.S. Jung Y.M. Park et al. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398 Clin Cancer Res 7 2001 1410-1418
11. M.A. Rahman D.K. Dhar E. Yamaguchi et al. Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: Possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases Clin Cancer Res 7 2001 1325-1332
12. J. Leng C. Han A.J. Demetris et al. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: Evidence for Akt inhibition in celecoxib-induced apoptosis Hepatology 38 2003 756-768
13. A.S. Cheng H.L. Chan K.F. et al. To Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus-associated hepatocellular carcinoma Int J Oncol 24 2004 853-860
14. T. Ikeda S. Tozuka Y. Hasumura et al. Prostaglandin-E-producing hepatocellular carcinoma with hypercalcemia Cancer 61 1988 1813-1814
15. 1 transactivates EGFR/Met receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J Cell Physiol [in press].
16. B.M. Bayer M.A. Beaven Evidence that indomethacin reversibly inhibits cell growth in the G1 phase of the cell cycle Biochem Pharmacol 28 1979 441-443
17. M.A. Kern D. Schubert D. Sahi et al. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells Hepatology 36 2002 885-894
18. G. Tian J.P. Yu H.S. Luo et al. Effect of nimesulide on proliferation and apoptosis of human hepatoma SMMC-7721 cells World J Gastroenterol 8 2002 483-487
19. K.Q. Hu C.H. Yu Y. Mineyama et al. Inhibited proliferation of cyclooxygenase-2 expressing human hepatoma cells by NS-398, a selective COX-2 inhibitor Int J Oncol 22 2003 757-763
20. D. Fodera N. D'Alessandro A. Cusimano et al. Induction of Apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors Ann N Y Acad Sci 1028 2004 440-449
21. M.K. Park S.Y. Hwang J.O. Kim et al. NS398 inhibits the growth of Hep3B human hepatocellular carcinoma cells via caspase-independent apoptosis Mol Cells 17 2004 45-50
22. D.S. Huang K.Z. Shen J.F. Wei et al. Specific COX-2 inhibitor NS398 induces apoptosis in human liver cancer cell line HepG2 through BCL-2 World J Gastroenterol 11 2005 204-207
23. J. Cheng H. Imanishi Y. Amuro et al. NS-398, a selective cyclooxygenase 2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines Int J Cancer 99 2002 755-761
24. T. Endoh Q. Tang A. Denda et al. Inhibition by acetylsalicylic acid, a cyclo-oxygenase inhibitor, and p-bromophenacylbromide, a phospholipase A2 inhibitor, of both cirrhosis and enzyme-altered nodules caused by a choline-deficient, l -amino acid-defined diet in rats Carcinogenesis 17 1996 467-475
25. A. Denda Q. Tang T. Endoh et al. Prevention by acetylsalicylic acid of liver cirrhosis and carcinogenesis as well as generations of 8-hydroxydeoxyguanosine and thiobarbituric acid-reactive substances caused by a choline-deficient, l -amino acid-defined diet in rats Carcinogenesis 15 1994 1279-1283
26. A. Denda T. Endoh Q. Tang et al. Prevention by inhibitors of arachidonic acid cascade of liver carcinogenesis, cirrhosis and oxidative DNA damage caused by a choline-deficient, l -amino acid-defined diet in rats Mutat Res 402 1998 279-288
27. A. Denda H. Ura T. Tsujiuchi et al. Possible involvement of arachidonic acid metabolism in phenobarbital promotion of hepatocarcinogenesis Carcinogenesis 10 1989 1929-1935
28. T. Tanaka T. Kojima A. Okumura et al. Inhibitory effect of the non-steroidal anti-inflammatory drugs, indomethacin and piroxicam on 2-acetylaminofluorene-induced hepatocarcinogenesis in male ACI/N rats Cancer Lett 68 1993 111-118
29. C. Gupta M. Banks H. Shinozuka Elevated levels of prostaglandin E2 in the liver of rats fed a choline deficient diet: Possible involvement in liver tumor promotion Cancer Lett 46 1989 129-135
30. M.A. Kern M.M. Schoneweiss D. Sahi et al. Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice Carcinogenesis 25 2004 1193-1199
31. L. Marquez-Rosado M.C. Trejo-Solis C.M. Garcia-Cuellar et al. Celecoxib, a cyclooxygenase-2 inhibitor, prevents induction of liver preneoplastic lesions in rats J Hepatol 43 2005 653-660
32. E.A. Dennis Diversity of group types, regulation, and function of phospholipase A2 J Biol Chem 269 1994 13057-13060
33. E.A. Dennis The growing phospholipase A2 superfamily of signal transduction enzymes Trends Biochem Sci 22 1997 1-2
34. J. Balsinde M.A. Balboa P.A. Insel et al. Regulation and inhibition of phospholipase A2 Annu Rev Pharmacol Toxicol 39 1999 175-189
35. R.N. Dubois S.B. Abramson L. Crofford et al. Cyclooxygenase in biology and disease FASEB J 12 1998 1063-1073
36. K.M. Verburg T.J. Maziasz E. Weiner et al. Cox-2-specific inhibitors: definition of a new therapeutic concept Am J Ther 8 2001 49-64
37. F. Marks K. Muller-Decker G. Furstenberger A causal relationship between unscheduled eicosanoid signaling and tumor development: Cancer chemoprevention by inhibitors of arachidonic acid metabolism Toxicology 153 2000 11-26
38. E. Fosslien Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia Crit Rev Clin Lab Sci 37 2000 431-502
39. D.B. Fournier G.B. Gordon COX-2 and colon cancer: Potential targets for chemoprevention J Cell Biochem Suppl. 34 2000 97-102
40. S. Gately The contributions of cyclooxygenase-2 to tumor angiogenesis Cancer Metastasis Rev 19 2000 19-27
41. C.S. Williams M. Mann R.N. DuBois The role of cyclooxygenases in inflammation, cancer, and development Oncogene 18 1999 7908-7916
42. F.A. Fitzpatrick R. Soberman Regulated formation of eicosanoids J Clin Invest 107 2001 1347-1351
43. W.L. Smith R. Langenbach Why there are two cyclooxygenase isozymes J Clin Invest 107 2001 1491-1495
44. W.L. Smith D.L. DeWitt R.M. Garavito Cyclooxygenases: Structural, cellular, and molecular biology Annu Rev Biochem 69 2000 145-182
45. R.A. Gupta R.N. Dubois Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2 Nat Rev Cancer 1 2001 11-21
46. D.L. Simmons R.M. Botting T. Hla Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition Pharmacol Rev 56 2004 387-437
47. V.L. Schuster Molecular mechanisms of prostaglandin transport Annu Rev Physiol 60 1998 221-242
48. A.J. Dannenberg N.K. Altorki J.O. Boyle et al. Cyclo-oxygenase 2: A pharmacological target for the prevention of cancer Lancet Oncol 2 2001 544-551
49. G. Gasparini R. Longo R. Sarmiento et al. Inhibitors of cyclo-oxygenase 2: A new class of anticancer agents? Lancet Oncol 4 2003 605-615
50. J.K. Reddy T. Hashimoto Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: An adaptive metabolic system Annu Rev Nutr 21 2001 193-230
51. C. Qi Y. Zhu J.K. Reddy Peroxisome proliferator-activated receptors, coactivators, and downstream targets Cell Biochem Biophys 32 Spring 2000 187-204
52. J. Vamecq N. Latruffe Medical significance of peroxisome proliferator-activated receptors Lancet 354 1999 141-148
53. J.C. Fruchart P. Duriez B. Staels Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis Curr Opin Lipidol 10 1999 245-257
54. I. Pineda Torra P. Gervois B. Staels Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging Curr Opin Lipidol 10 1999 151-159
55. B. Desvergne W. Wahli Peroxisome proliferator-activated receptors: nuclear control of metabolism Endocr Rev 20 1999 649-688
56. V. Giguere Orphan nuclear receptors: From gene to function Endocr Rev 20 1999 689-725
57. F.J. Gonzalez The role of peroxisome proliferator activated receptor alpha in peroxisome proliferation, physiological homeostasis, and chemical carcinogenesis Adv Exp Med Biol 422 1997 109-125
58. B.M. Forman P. Tontonoz J. Chen et al. 15-Deoxy-delta 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma Cell 83 1995 803-812
59. S.A. Kliewer J.M. Lenhard T.M. Willson et al. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation Cell 83 1995 813-819
60. P.R. Devchand H. Keller J.M. Peters et al. The PPARalpha-leukotriene B4 pathway to inflammation control [see comments] Nature 384 1996 39-43
61. C. Han A.J. Demetris G. Michalopoulos et al. 85-kDa cPLA(2) plays a critical role in PPAR-mediated gene transcription in human hepatoma cells Am J Physiol Gastrointest Liver Physiol 282 2002 G586-G597
62. R. Pawliczak C. Han X.L. Huang et al. 85-kDa cytosolic phospholipase A2 mediates peroxisome proliferator-activated receptor gamma activation in human lung epithelial cells J Biol Chem 277 2002 33153-33163
63. R. Pawliczak C. Logun P. Madara et al. Cytosolic phospholipase A2 Group IValpha but not secreted phospholipase A2 Group IIA, V, or X induces interleukin-8 and cyclooxygenase-2 gene and protein expression through peroxisome proliferator-activated receptors gamma 1 and 2 in human lung cells J Biol Chem 279 2004 48550-48561
64. T.C. Tang R.T. Poon C.P. Lau et al. Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma World J Gastroenterol 11 2005 1896-1902
65. H.R. Herschman Prostaglandin synthase 2 Biochim Biophys Acta 1299 1996 125-140
66. N.A. Callejas L. Bosca C.S. Williams et al. Regulation of cyclooxygenase 2 expression in hepatocytes by CCAAT/enhancer-binding proteins Gastroenterology 119 2000 493-501
67. E. Lara-Pezzi M.V. Gomez-Gaviro B.G. Galvez et al. The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression J Clin Invest 110 2002 1831-1838
68. A.S. Cheng H.L. Chan W.K. Leung et al. Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: Implication of HBx in upregulation of COX-2 Mod Pathol 17 2004 1169-1179
69. G. Waris A. Siddiqui Hepatitis C virus stimulates the expression of cyclooxygenase-2 via oxidative stress: Role of prostaglandin E2 in RNA replication J Virol 79 2005 9725-9734
70. M. Joo Y.S. Hahn M. Kwon et al. Hepatitis C virus core protein suppresses NF-kappaB activation and cyclooxygenase-2 expression by direct interaction with IkappaB kinase beta J Virol 79 2005 7648-7657
71. R. Jhaveri P. Kundu A.M. Shapiro et al. Effect of heptitis C virus core protein on cellular gene expression: Specific inhibition of cyclooxygenase 2 J Infect Dis 191 2005 1498-1506
72. Y. Araki S. Okamura S.P. Hussain et al. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways Cancer Res 63 2003 728-734
73. H. Murata S. Tsuji M. Tsujii et al. Promoter hypermethylation silences cyclooxygenase-2 (Cox-2) and regulates growth of human hepatocellular carcinoma cells Lab Invest 84 2004 1050-1059
74. A. Di Popolo A. Memoli A. Apicella et al. IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells Oncogene 19 2000 5517-5524
75. A. Marchio M. Meddeb P. Pineau et al. Recurrent chromosomal abnormalities in hepatocellular carcinoma detected by comparative genomic hybridization Genes Chromosomes Cancer 18 1997 59-65
76. F. Niketeghad H.J. Decker W.H. Caselmann et al. Frequent genomic imbalances suggest commonly altered tumour genes in human hepatocarcinogenesis Br J Cancer 85 2001 697-704
77. M. Murakami T. Kambe S. Shimbara et al. Functional coupling between various phospholipase A2s and cyclooxygenases in immediate and delayed prostanoid biosynthetic pathways J Biol Chem 274 1999 3103-3115
78. S. Morinaga Y. Yamamoto Y. Noguchi et al. Cyclooxygenase-2 mRNA is up-regulated in cirrhotic or chronic hepatitis liver adjacent to hepatocellular carcinoma J Gastroenterol Hepatol 17 2002 1110-1116
79. J. Cheng H. Imanishi H. Iijima et al. Expression of cyclooxygenase2 and cytosolic phospholipase A(2) in the liver tissue of patients with chronic hepatitis and liver cirrhosis Hepatol Res 23 2002 185-195
80. N.A. Mohammed S.A. Abd El-Aleem H.A. El-Hafiz et al. Distribution of constitutive (COX-1) and inducible (COX-2) cyclooxygenase in postviral human liver cirrhosis: A possible role for COX-2 in the pathogenesis of liver cirrhosis J Clin Pathol 57 2004 350-354
81. E.A. Akriviadis J.M. Llovet S.C. Efremidis et al. Hepatocellular carcinoma Br J Surg 85 1998 1319-1331
82. R.J. Groszmann Hyperdynamic state in chronic liver diseases J Hepatol 17 Suppl. 2 1993 S38-S40
83. M. Tsujii S. Kawano S. Tsuji et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells Cell 93 1998 705-716
84. H. Yamamoto M. Kondo S. Nakamori et al. JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis1 Gastroenterology 125 2003 556-571
85. O.N. El-Assal A. Yamanoi Y. Soda et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: Possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver Hepatology 27 1998 1554-1562
86. P. Andreone C. Cursaro G. Gasbarrini et al. Interferon-alpha increases prostaglandin E2 production by cultured liver biopsy in patients with chronic viral hepatitis: Can non-steroidal anti-inflammatory drugs improve the therapeutic response to interferon? J Hepatol 19 1993 228-231
87. S. Giambartolomei M. Artini C. Almerighi et al. Nonsteroidal anti-inflammatory drug metabolism potentiates interferon alfa signaling by increasing STAT1 phosphorylation Hepatology 30 1999 510-516
88. P. Andreone A. Gramenzi C. Cursaro et al. Interferon-alpha combined with ketoprofen as treatment of naive patients with chronic hepatitis C: A randomized controlled trial J Viral Hepat 10 2003 306-309
89. G.Z. Leu T.Y. Lin J.T. Hsu Anti-HCV activities of selective polyunsaturated fatty acids Biochem Biophys Res Commun 318 2004 275-280
90. M. Okita K. Tomioka Y. Ota et al. Arachidonic acid in mononuclear cells and its clinical significance in HCV cirrhotic patients Nutrition 19 2003 727-732
91. E.J. Moon C.H. Jeong J.W. Jeong et al. Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-inducible factor-1alpha FASEB J 18 2004 382-384
92. A.S. Cheng H.L. Chan N.W. Leung et al. Expression of cyclooxygenase-2 in chronic hepatitis B and the effects of anti-viral therapy Aliment Pharmacol Ther 16 2002 251-260
93. A.A. Nanji L. Miao P. Thomas et al. Enhanced cyclooxygenase-2 gene expression in alcoholic liver disease in the rat [see comments] Gastroenterology 112 1997 943-951
94. A.A. Nanji D. Zakim A. Rahemtulla et al. Dietary saturated fatty acids down-regulate cyclooxygenase-2 and tumor necrosis factor alfa and reverse fibrosis in alcohol-induced liver disease in the rat Hepatology 26 1997 1538-1545
95. K. Okuda Hepatocellular carcinoma J Hepatol 32 2000 225-237
96. O. Hino K. Kajino T. Umeda Understanding the hypercarcinogenic state in chronic hepatitis: A clue to the prevention of human hepatocellular carcinoma J Gastroenterol 37 2002 883-887
97. T. Kosaka A. Miyata H. Ihara et al. Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2 Eur J Biochem 221 1994 889-897
98. J. Sirois L.O. Levy D.L. Simmons et al. Characterization and hormonal regulation of the promoter of the rat prostaglandin endoperoxide synthase 2 gene in granulosa cells. Identification of functional and protein-binding regions J Biol Chem 268 1993 12199-12206
99. B.S. Fletcher D.A. Kujubu D.M. Perrin et al. Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase J Biol Chem 267 1992 4338-4344
100. J.W. Lim H. Kim K.H. Kim Nuclear factor-kappaB regulates cyclooxygenase-2 expression and cell proliferation in human gastric cancer cells Lab Invest 81 2001 349-360
101. O. Nunez A. Fernandez-Martinez P.L. Majano et al. Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: Role of viral core and NS5A proteins Gut 53 2004 1665-1672
102. A.Y. Hui A.S. Cheng H.L. Chan et al. Effect of prostaglandin E2 and prostaglandin I2 on PDGF-induced proliferation of LI90, a human hepatic stellate cell line Prostaglandins Leukot Essent Fatty Acids 71 2004 329-333
103. J. Cheng H. Imanishi W. Liu et al. Inhibition of the expression of alpha-smooth muscle actin in human hepatic stellate cell line, LI90, by a selective cyclooxygenase 2 inhibitor, NS-398 Biochem Biophys Res Commun 297 2002 1128-1134
104. A.Y. Hui A.J. Dannenberg J.J. Sung et al. Prostaglandin E2 inhibits transforming growth factor beta 1-mediated induction of collagen alpha 1(I) in hepatic stellate cells J Hepatol 41 2004 251-258
105. E. Efsen A. Bonacchi S. Pastacaldi et al. Agonist-specific regulation of monocyte chemoattractant protein-1 expression by cyclooxygenase metabolites in hepatic stellate cells Hepatology 33 2001 713-721
106. A. Planaguma J. Claria R. Miquel et al. The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation FASEB J 19 2005 1120-1122
107. M. Casado N.A. Callejas J. Rodrigo et al. Contribution of cyclooxygenase 2 to liver regeneration after partial hepatectomy FASEB J 15 2001 2016-2018
108. T.P. Reilly J.N. Brady M.R. Marchick et al. A protective role for cyclooxygenase-2 in drug-induced liver injury in mice Chem Res Toxicol 14 2001 1620-1628
109. S. Abiru K. Nakao T. Ichikawa et al. Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells Hepatology 35 2002 1117-1124
110. R. Mayoral A. Fernandez-Martinez L. Bosca et al. Prostaglandin E2 promotes migration and adhesion in hepatocellular carcinoma cells Carcinogenesis 26 2005 753-761
111. N.A. Callejas M. Casado M.J. Diaz-Guerra et al. Expression of cyclooxygenase-2 promotes the release of matrix metalloproteinase-2 and -9 in fetal rat hepatocytes Hepatology 33 2001 860-867
112. F. Cianchi C. Cortesini P. Bechi et al. Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer Gastroenterology 121 2001 1339-1347
113. I.O. Ng R.T. Poon J.M. Lee et al. Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma Am J Clin Pathol 116 2001 838-845
114. R.T. Poon I.O. Ng C. Lau et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: A prospective study Ann Surg 233 2001 227-235
115. S. Murono H. Inoue T. Tanabe et al. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells Proc Natl Acad Sci USA 98 2001 6905-6910
116. M. Sonoshita K. Takaku N. Sasaki et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice Nat Med 7 2001 1048-1051
117. M. Mise S. Arii H. Higashituji et al. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor Hepatology 23 1996 455-464
118. I. Vivanco C.L. Sawyers The phosphatidylinositol 3-Kinase AKT pathway in human cancer Nat Rev Cancer 2 2002 489-501
119. J.R. Testa A. Bellacosa AKT plays a central role in tumorigenesis Proc Natl Acad Sci USA 98 2001 10983-10985
120. M.A. Lawlor D.R. Alessi PKB/Akt: A key mediator of cell proliferation, survival and insulin responses? J Cell Sci 114 2001 2903-2910
121. C.M. Schmidt Y. Wang C. Wiesenauer Novel combination of cyclooxygenase-2 and MEK inhibitors in human hepatocellular carcinoma provides a synergistic increase in apoptosis J Gastrointest Surg 7 2003 1024-1033
122. A.L. Hsu T.T. Ching D.S. Wang et al. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2 J Biol Chem 275 2000 11397-11403
123. S. Grosch I. Tegeder E. Niederberger et al. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib FASEB J 15 2001 2742-2744
124. S. Arico S. Pattingre C. Bauvy et al. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line J Biol Chem 277 2002 27613-27621
125. C. Waskewich R.D. Blumenthal H. Li et al. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines Cancer Res 62 2002 2029-2033
126. E.D. Rosen B.M. Spiegelman Ppargamma: A nuclear regulator of metabolism, differentiation, and cell growth J Biol Chem 276 2001 37731-37734
127. B.M. Spiegelman Peroxisome proliferator-activated receptor gamma: A key regulator of adipogenesis and systemic insulin sensitivity Eur J Med Res 2 1997 457-464
128. O. Gavrilova M. Haluzik K. Matsusue et al. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass J Biol Chem 278 2003 34268-34276
129. C. Han A.J. Demetris G.K. Michalopoulos et al. PPARgamma ligands inhibit cholangiocarcinoma cell growth through p53-dependent GADD45 and p21 pathway Hepatology 38 2003 167-177
130. L. Michalik B. Desvergne W. Wahli Peroxisome-proliferator-activated receptors and cancers: Complex stories Nat Rev Cancer 4 2004 61-70
131. H. Koga S. Sakisaka M. Harada et al. Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines Hepatology 33 2001 1087-1097
132. W. Motomura N. Takahashi M. Nagamine et al. Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells Int J Cancer 108 2004 41-46
133. K.L. Schaefer K. Wada H. Takahashi et al. Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells Cancer Res 65 2005 2251-2259
134. M.A. Rumi H. Sato S. Ishihara et al. Peroxisome proliferator-activated receptor gamma ligand-induced growth inhibition of human hepatocellular carcinoma Br J Cancer 84 2001 1640-1647
135. H. Koga M. Harada M. Ohtsubo et al. Troglitazone induces p27Kip1-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells Hepatology 37 2003 1086-1096
136. P. Tontonoz S. Singer B.M. Forman et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor Proc Natl Acad Sci USA 94 1997 237-241
137. G.D. Demetri C.D. Fletcher E. Mueller et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma Proc Natl Acad Sci USA 96 1999 3951-3956
138. P. Sarraf E. Mueller D. Jones et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma Nat Med 4 1998 1046-1052
139. P. Sarraf E. Mueller W.M. Smith et al. Loss-of-function mutations in PPAR gamma associated with human colon cancer Mol Cell 3 1999 799-804
140. R.N. DuBois R. Gupta J. Brockman et al. The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers Carcinogenesis 19 1998 49-53
141. E. Elstner C. Muller K. Koshizuka et al. Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice Proc Natl Acad Sci USA 95 1998 8806-8811
142. E. Mueller M. Smith P. Sarraf et al. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer Proc Natl Acad Sci USA 97 2000 10990-10995
143. T. Kubota K. Koshizuka E.A. Williamson et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo Cancer Res 58 1998 3344-3352
144. K.I. Nakashiro Y. Hayashi A. Kita et al. Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells Am J Pathol 159 2001 591-597
145. T.H. Chang E. Szabo Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer Cancer Res 60 2000 1129-1138
146. T. Ikezoe C.W. Miller S. Kawano et al. Mutational analysis of the peroxisome proliferator-activated receptor gamma gene in human malignancies Cancer Res 61 2001 5307-5310
147. C.E. Clay A.M. Namen G. Atsumi et al. Magnitude of peroxisome proliferator-activated receptor-gamma activation is associated with important and seemingly opposite biological responses in breast cancer cells J Invest Med 49 2001 413-420
148. E. Saez J. Rosenfeld A. Livolsi et al. PPAR gamma signaling exacerbates mammary gland tumor development Genes Dev 18 2004 528-540
149. A.M. Lefebvre I. Chen P. Desreumaux et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice Nat Med 4 1998 1053-1057
150. E. Saez P. Tontonoz M.C. Nelson et al. Activators of the nuclear receptor PPARgamma enhance colon polyp formation Nat Med 4 1998 1058-1061
151. G.D. Girnun W.M. Smith S. Drori et al. APC-dependent suppression of colon carcinogenesis by PPARgamma Proc Natl Acad Sci USA 99 2002 13771-13776
152. C. Han A.J. Demetris Y. Liu et al. Transforming growth factor-beta (TGF-beta) activates cytosolic phospholipase A2alpha (cPLA2alpha)-mediated prostaglandin E2 (PGE)2/EP1 and peroxisome proliferator-activated receptor-gamma (PPAR-gamma)/Smad signaling pathways in human liver cancer cells. A novel mechanism for subversion of TGF-beta-induced mitoinhibition J Biol Chem 279 2004 44344-44354
153. L.C. Bell-Parikh T. Ide J.A. Lawson et al. Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma J Clin Invest 112 2003 945-955
154. W.S. Powell 15-Deoxy-delta 12,14-PGJ2: Endogenous PPARgamma ligand or minor eicosanoid degradation product J Clin Invest 112 2003 828-830
155. J.K. Reddy D.L. Azarnoff C.E. Hignite Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens Nature 283 1980 397-398
156. S.J. Roberts-Thomson Peroxisome proliferator-activated receptors in tumorigenesis: Targets of tumour promotion and treatment Immunol Cell Biol 78 2000 436-441
157. J.C. Corton P.J. Lapinskas F.J. Gonzalez Central role of PPARalpha in the mechanism of action of hepatocarcinogenic peroxisome proliferators Mutat Res 448 2000 139-151
158. F.J. Gonzalez J.M. Peters R.C. Cattley Mechanism of action of the nongenotoxic peroxisome proliferators: Role of the peroxisome proliferator-activator receptor alpha J Natl Cancer Inst 90 1998 1702-1709
159. B.G. Lake Peroxisome proliferation: Current mechanisms relating to nongenotoxic carcinogenesis Toxicol Lett 82-83 1995 673-681
160. J.M. Peters R.C. Cattley F.J. Gonzalez Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643 Carcinogenesis 18 1997 2029-2033
161. K. Meyer J.S. Lee P.A. Dyck et al. Molecular profiling of hepatocellular carcinomas developing spontaneously in acyl-CoA oxidase deficient mice: comparison with liver tumors induced in wild-type mice by a peroxisome proliferator and a genotoxic carcinogen Carcinogenesis 24 2003 975-984
162. J.K. Reddy M.S. Rao Oxidative DNA damage caused by persistent peroxisome proliferation: Its role in hepatocarcinogenesis Mutat Res 214 1989 63-68
163. A.V. Yeldandi M.S. Rao J.K. Reddy Hydrogen peroxide generation in peroxisome proliferator-induced oncogenesis Mutat Res 448 2000 159-177
164. M.S. Rao N.D. Lalwani T.K. Watanabe et al. Inhibitory effect of antioxidants ethoxyquin and 2(3)-tert-butyl-4-hydroxyanisole on hepatic tumorigenesis in rats fed ciprofibrate, a peroxisome proliferator Cancer Res 44 1984 1072-1076
165. J.M. Peters T. Aoyama R.C. Cattley et al. Role of peroxisome proliferator-activated receptor alpha in altered cell cycle regulation in mouse liver Carcinogenesis 19 1998 1989-1994
166. B.J. Ledwith T.E. Johnson L.K. Wagner et al. Growth regulation by peroxisome proliferators: Opposing activities in early and late G1 Cancer Res 56 1996 3257-3264
167. Y. Motoki H. Tamura R. Morita et al. Decreased hepatocyte growth factor level by Wy-14,643, non-genotoxic hepatocarcinogen in F-344 rats Carcinogenesis 18 1997 1303-1309
168. A.C. Bayly R.A. Roberts C. Dive Suppression of liver cell apoptosis in vitro by the non-genotoxic hepatocarcinogen and peroxisome proliferator nafenopin J Cell Biol 125 1994 197-203
169. J.G. Christensen A.J. Gonzales R.C. et al. Cattley Regulation of apoptosis in mouse hepatocytes and alteration of apoptosis by nongenotoxic carcinogens Cell Growth Differ 9 1998 815-825
170. J.G. Christensen E.H. Romach L.N. Healy et al. Altered bcl-2 family expression during non-genotoxic hepatocarcinogenesis in mice Carcinogenesis 20 1999 1583-1590
171. R.A. Roberts N.H. James S.C. Hasmall et al. Apoptosis and proliferation in nongenotoxic carcinogenesis: Species differences and role of PPARalpha Toxicol Lett 112-113 2000 49-57
172. R.A. Roberts N.H. James N.J. Woodyatt et al. Evidence for the suppression of apoptosis by the peroxisome proliferator activated receptor alpha (PPAR alpha) Carcinogenesis 19 1998 43-48
173. M. Rolfe N.H. James R.A. Roberts Tumour necrosis factor alpha (TNF alpha) suppresses apoptosis and induces DNA synthesis in rodent hepatocytes: A mediator of the hepatocarcinogenicity of peroxisome proliferators? Carcinogenesis 18 1997 2277-2280
174. N.H. James J.H. Gill R. Brindle et al. Peroxisome proliferator-activated receptor (PPAR) alpha-regulated growth responses and their importance to hepatocarcinogenesis Toxicol Lett 102-103 1998 91-96
175. S. Yu W.Q. Cao P. Kashireddy et al. Human peroxisome proliferator-activated receptor alpha (PPARalpha) supports the induction of peroxisome proliferation in PPARalpha-deficient mouse liver J Biol Chem 276 2001 42485-42491
176. M. Hopfner A.P. Sutter A. Huether et al. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma J Hepatol 41 2004 1008-1016
177. E. Schiffer C. Housset W. Cacheux et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis Hepatology 41 2005 307-314
178. C.J. Barnes R. Kumar Biology of the epidermal growth factor receptor family Cancer Treat Res 119 2004 1-13
179. M. Ranson Epidermal growth factor receptor tyrosine kinase inhibitors Br J Cancer 90 2004 2250-2255
180. S.S. Sridhar L. Seymour F.A. Shepherd Inhibitors of epidermal-growth-factor receptors: A review of clinical research with a focus on non-small-cell lung cancer Lancet Oncol 4 2003 397-406
181. B.F. El-Rayes P.M. LoRusso Targeting the epidermal growth factor receptor Br J Cancer 91 2004 418-424
182. V. Grunwald M. Hidalgo Developing inhibitors of the epidermal growth factor receptor for cancer treatment J Natl Cancer Inst 95 2003 851-867
183. N. Prenzel O.M. Fischer S. Streit et al. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification Endocr Relat Cancer 8 2001 11-31
184. H. Tsubouchi Sustained activation of epidermal growth factor receptor in cholangiocarcinoma: A potent therapeutic target? J Hepatol 41 2004 859-861
185. J.H. Yoon G.Y. Gwak H.S. Lee et al. Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells J Hepatol 41 2004 808-814
186. Y.Y. Jan T.S. Yeh J.N. Yeh et al. Expression of epidermal growth factor receptor, apomucins, matrix metalloproteinases, and p53 in rat and human cholangiocarcinoma: Appraisal of an animal model of cholangiocarcinoma Ann Surg 240 2004 89-94
187. K. Harada T. Terada Y. Nakanuma Detection of transforming growth factor-alpha protein and messenger RNA in hepatobiliary diseases by immunohistochemical and in situ hybridization techniques Hum Pathol 27 1996 787-792
188. Y. Ito T. Takeda Y. Sasaki et al. Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma Pathol Res Pract 197 2001 95-100
189. R. Pai B. Soreghan I.L. Szabo et al. Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy Nat Med 8 2002 289-293
190. F.G. Buchanan D. Wang F. Bargiacchi et al. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor J Biol Chem 278 2003 35451-35457
191. J. Shao S.B. Lee H. Guo et al. Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin Cancer Res 63 2003 5218-5223
192. C. Han T. Wu Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invation through EP1 receptor-mediated activation of epidermal growth factor receptor and AKT J Biol Chem 2005
193. Y. Ito T. Takeda M. Sakon et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma Br J Cancer 84 2001 1377-1383
194. C. Vanchieri Vioxx withdrawal alarms cancer prevention researchers J Natl Cancer Inst 96 2004 1734-1735
195. J. Couzin Clinical trials. Nail-biting time for trials of COX-2 drugs Science 306 2004 1673-1675
196. G. Tortora R. Caputo V. Damiano et al. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect Clin Cancer Res 9 2003 1566-1572
197. C.J. Torrance P.E. Jackson E. Montgomery et al. Combinatorial chemoprevention of intestinal neoplasia Nat Med 6 2000 1024-1028
198. B. Ahn B.S. Han D.J. Kim et al. Immunohistochemical localization of inducible nitric oxide synthase and 3-nitrotyrosine in rat liver tumors induced by N-nitrosodiethylamine Carcinogenesis 20 1999 1337-1344
199. M. Jaiswal N.F. LaRusso L.J. Burgart et al. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism Cancer Res 60 2000 184-190
200. M. Jaiswal N.F. LaRusso R.A. Shapiro et al. Nitric oxide-mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes Gastroenterology 120 2001 190-199
201. N.J. Torok H. Higuchi S. Bronk et al. Nitric oxide inhibits apoptosis downstream of cytochrome C release by nitrosylating caspase 9 Cancer Res 62 2002 1648-1653
202. O. Fantappie E. Masini I. Sardi et al. The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line Hepatology 35 2002 843-852
203. C.V. Rao C. Indranie B. Simi et al. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor Cancer Res 62 2002 165-170
204. T. Chen R.G. Nines S.M. Peschke et al. Chemopreventive effects of a selective nitric oxide synthase inhibitor on carcinogen-induced rat esophageal tumorigenesis Cancer Res 64 2004 3714-3717
205. W.E. Hardman (n - 3) fatty acids and cancer therapy J Nutr 134 2004 3427S-3430S
206. S.C. Larsson M. Kumlin M. Ingelman-Sundberg Dietary long-chain n - 3 fatty acids for the prevention of cancer: A review of potential mechanisms Am J Clin Nutr 79 2004 935-945
207. J. Singh R. Hamid B.S. Reddy Dietary fat and colon cancer: Modulation of cyclooxygenase-2 by types and amount of dietary fat during the postinitiation stage of colon carcinogenesis Cancer Res 57 1997 3465-3470
208. G. Calviello F. Di Nicuolo S. Gragnoli et al. n - 3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced ERK-1 and -2 and HIF-1alpha induction pathway Carcinogenesis 25 2004 2303-2310
209. M. Jelinska A. Tokarz R. Oledzka et al. Effects of dietary linseed, evening primrose or fish oils on fatty acid and prostaglandin E2 contents in the rat livers and 7,12-dimethylbenz[a]anthracene-induced tumours Biochim Biophys Acta 1637 2003 193-199
210. Y. Kim S.K. Ji H. Choi Modulation of liver microsomal monooxygenase system by dietary n - 6/n - 3 ratios in rat hepatocarcinogenesis Nutr Cancer 37 2000 65-72
211. K.M. Rahman S. Sugie K. Okamoto et al. Modulating effects of diets high in omega-3 and omega-6 fatty acids in initiation and postinitiation stages of diethylnitrosamine-induced hepatocarcinogenesis in rats Jpn J Cancer Res 90 1999 31-39
212. S. Sugie K. Okamoto T. Tanaka et al. Effect of fish oil on the development of AOM-induced glutathione S-transferase placental form positive hepatocellular foci in male F344 rats Nutr Cancer 24 1995 187-195
213. G. Calviello P. Palozza P. Franceschelli et al. Eicosapentaenoic acid inhibits the growth of liver preneoplastic lesions and alters membrane phospholipid composition and peroxisomal beta-oxidation Nutr Cancer 34 1999 206-212
214. G. Calviello P. Palozza E. Piccioni et al. Dietary supplementation with eicosapentaenoic and docosahexaenoic acid inhibits growth of Morris hepatocarcinoma 3924A in rats: Effects on proliferation and apoptosis Int J Cancer 75 1998 699-705
215. D. Mukherjee S.E. Nissen E.J. Topol Risk of cardiovascular events associated with selective COX-2 inhibitors JAMA 286 2001 954-959
216. W.B. White G. Faich A. Whelton et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac Am J Cardiol 89 2002 425-430
217. G.A. Fitzgerald Coxibs and cardiovascular disease N Engl J Med 351 2004 1709-1711